ACE, angiotensinogen and obesity: A potential pathway leading to hypertension

Journal of Human Hypertension

Volumn 11, Issue 2, 1997, Pages 107-111

  Cooper, R ^a   McFarlane Anderson, N ^b   Bennett, F I ^b   Wilks, R ^b   Puras, A ^a   Tewksbury, D ^c   Ward, R ^d   Forrester, T ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b UNIVERSITY OF THE WEST INDIES   (Jamaica)

^c MARSHFIELD CLINIC   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

ACE; Angiotensinogen; Blood pressure; Genotype; Obesity

Indexed keywords

ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; AMINO ACID SUBSTITUTION; ANGIOTENSIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; JAMAICA; MALE; OBESITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR;

EID: 0030908764     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000391     Document Type: Article

References (31)

1. De Leew P, Birkenhager W. The renal circulation in essential hypertension. J Hypertens 1983; 1: 321-331.
2. Hall J, Mizelle H, Woods L. The renin-angiotensin system and long-term regulation of arterial pressure. J Hypertens 1986; 4: 387-397.
3. Tiret L et al. Evidence from combined segregation and linkage analysis, that a variant of the angiotensin-converting enzyme (ACE) gene control plasma ACE levels. Am J Hum Genet 1992; 51; 197-205.
4. Jeunemaitre X et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71: 169-180.
5. Caulfield M et al. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 1994; 330: 1629-1633.
6. Cambien F et al. Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy study. Am J Hum Genet 1988; 43: 774-780.
7. McKenzie CA et al. Segregation and linkage analysis of serum angiotensin I converting enzyme levels: evidence for two quantitative trait loci. Am J Hum Genet 1995; 57: 1426-1435.
8. Tewksbury DA. Angiotensinogen. Federation Proc 1983; 42: 2724-2728.
9. Rocchini A, Moorehead C, De Remer S, Boondie D. Pathogenesis of weight related changes in blood pressure in dogs. Hypertension 1989; 13: 922-928.
10. Tick M et al. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304: 930-933.
11. Weinsier R et al. Obesity-related hypertension: evaluation of separate effects of energy restriction and weight reduction on hemodynamic and endocrine status. Am J Med 1991; 90: 460-468.
12. Hall J. Renal and cardiovascular mechanisms of hypertension in obesity. Hypertension 1994; 23: 381-394.
13. Licata G et al. Central obesity and hypertension. Relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects. Am J Hypertens 1994; 7: 312-320.
14. Forrester T et al. The insertion/deletion polymorphism of the ACE genes, serum ACE activity and blood pressure in Jamaicans. Am J Hypertension, in press.
15. Ataman S et al. Standardization of blood pressure in an international collaborative study. J Clin Epidemiol 1996; 49: 869-877.
16. Beneteau B et al. Automated kinetic assay of angiotensin-converting enzyme in serum. Clin Chem 1986; 32: 884-886.
17. Tewksbury D, Dart R. High molecular weight angiotensinogen levels in pregnant women. Hypertension 1982; 4: 729-734.
18. Cassis A, Saye J, Peach M. Location and regulation of rat angiotensinogen messenger RNA. Hypertension 1988; 11: 591-596.
19. Rotimi C et al. Angiotensinogen gene in human hypertension. Lack of an association of the 235T allele among African Americans. Hypertension 1994; 24: 591-594.
20. SAS Institute. SAS Users Guide: Statistics. 6th ed. Gary, NC: SAS Institute, 1990.
21. Hall J, Herrera G, Granger J. Renal pathophysiology in obesity-induced hypertension. Hypertension 1991; 18: 395.
22. Hall et al. Obesity, hyperinsulinemia, and hypertension: control of renal function and systemic hemodynamics. J Am Soc Nephrol 1990; 1: 490.
23. Frohlich E. Obesity hypertension: converting enzyme inhibitors and calcium antagonists. Hypertension 1991; 19 (Suppl I): I119-I123.
24. Dzau V. Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol 1987; 59: 59A-65A.
25. Tamura K et al. Molecular mechanism of adipogenic activation of the angiotensinogen gene. Hypertension 1994; 23: 364-368.
26. Saye J, Lynch K, Peach M. Changes in angiotensinogen messenger RNA in differentiating 3T3-F442A adipocytes. Hypertension 1990; 15: 867-871.
27. Frederich R, Kahn B, Peach M, Flier J. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992; 19: 339-344.
28. Cassis L, Lynch K, Peach M. Localization of angiotensinogen mRNA in rat aorta. Circ Res 1988; 62: 1259-1262.
29. Phillips M, Speakman E, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regulatory Peptides 1993; 434: 1-120.
30. Enalapril in Hypertension Study Group (UK): Enalapril in essential hypertension: a comparative study with propranolol. Br J Clin Pharmacol 1984; 18: 51-56.
31. McGrath B et al. Double blind study of dilevarol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension. J Cardiovasc Pharmacol 1990; 16: 831-838.